SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NeuroSense Plans Canadian PrimeC ALS Filing for March 2027

NeuroSense plans to file a Canadian application for its ALS drug PrimeC in March 2027, with new biomarker data.

NRSN

Related stories